APLS Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 43.91%. Apellis Pharmaceuticals's return on equity of -96.34% beat Arvinas's return on equity of -7.72%.

Apellis Pharmaceuticals has a consensus price target of $35.35, signalling upside risk potential of 99.83%. On the other hand Arvinas has an analysts' consensus of $19.36 which suggests that it could grow by 160.23%. Given that Arvinas has higher upside potential than Apellis Pharmaceuticals, analysts believe Arvinas is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.675, which suggesting that the stock is 32.462% less volatile than S&P 500. In comparison Arvinas has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.176%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are smaller than Arvinas quarterly revenues of $188.8M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Arvinas's net income of $82.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.84x versus 1.26x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of --. Apellis Pharmaceuticals's return on equity of -96.34% beat Kodiak Sciences's return on equity of --.

Apellis Pharmaceuticals has a consensus price target of $35.35, signalling upside risk potential of 99.83%. On the other hand Kodiak Sciences has an analysts' consensus of $6.80 which suggests that it could grow by 87.85%. Given that Apellis Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Apellis Pharmaceuticals is more attractive than Kodiak Sciences.

Apellis Pharmaceuticals has a beta of 0.675, which suggesting that the stock is 32.462% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.266, suggesting its more volatile than the S&P 500 by 126.64%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Kodiak Sciences quarterly revenues of --. Apellis Pharmaceuticals's net income of -$92.2M is lower than Kodiak Sciences's net income of -$57.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.84x versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -151.35%. Apellis Pharmaceuticals's return on equity of -96.34% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

Apellis Pharmaceuticals has a consensus price target of $35.35, signalling upside risk potential of 99.83%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 34.57%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.675, which suggesting that the stock is 32.462% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.301, suggesting its more volatile than the S&P 500 by 130.127%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.84x versus 27.96x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 23.33%. Apellis Pharmaceuticals's return on equity of -96.34% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Apellis Pharmaceuticals has a consensus price target of $35.35, signalling upside risk potential of 99.83%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $499.87 which suggests that it could grow by 13.38%. Given that Apellis Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.675, which suggesting that the stock is 32.462% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Apellis Pharmaceuticals's net income of -$92.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.84x versus 10.29x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.